focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,132.00
Bid: 12,130.00
Ask: 12,134.00
Change: -40.00 (-0.33%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,188.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: NatWest falls as UK FCA starts criminal action

Tue, 16th Mar 2021 08:50

(Alliance News) - Stock prices in London opened higher on Tuesday tracking global peers, while NatWest was lower after the City watchdog launched criminal proceedings against the state-backed lender.

The FTSE 100 index was up 40.41 points, or 0.6%, at 6,790.11. The mid-cap FTSE 250 index was up 123.33 points, or 0.5%, at 21,645.68. The AIM All-Share index was 0.3% higher at 1,202.98.

The Cboe UK 100 index was up 0.4% at 674.32. The Cboe 250 was up 0.4% at 19,243.66, and the Cboe Small Companies up 0.1% at 13,953.44.

In mainland Europe, the CAC 40 in Paris was up 0.2%, while the DAX 30 in Frankfurt was 0.5% higher.

In the FTSE 100, Barclays was the best performer, up 2.9%, after Credit Suisse raised the UK lender to Outperform from Neutral.

AstraZeneca was up 1.9% after the drugmaker said it has modified an existing agreement with the US government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody combination which is in late-stage development for the prevention and treatment of Covid-19.

In addition, Jefferies raised AstraZeneca to Buy from Hold.

The Anglo-Swedish firm said the new US government deal builds on earlier deals for a total of 200,000 doses with the US Department of Health & Human Service and Department of Defense.

The value of the extended agreement is USD205 million and is contingent on AZD7442 receiving an Emergency Use Authorisation from the US Food & Drug Administration. AstraZeneca said the total value of current agreements with the US government for the development and supply of AZD7442 in 2021 is about USD726 million.

The extended agreement is not anticipated to affect the company's financial guidance for 2021.

AstraZeneca also said it has completed the sale of its 27% stake in Viela Bio Inc to Horizon Therapeutics. It will receive USD775 million in cash proceeds and profit from the Viela stake sale, but this also isn't expected to affect its guidance for 2021.

At the other end of the large-caps, NatWest Group was the worst performer, 1.1% lower after the bank said the UK financial regulator has opened criminal proceedings over the bank's alleged failure to comply with money laundering regulations.

The UK Financial Conduct Authority started the investigation in July 2017 - covering the period from November 2011 to October 2016 - but has now decided to begin criminal proceedings against National Westminster Bank.

NatWest stressed it has been cooperating with the FCA's investigation.

Standard Chartered was down 0.9%, after Credit Suisse downgraded the Asia-focused bank to Underperform from Neutral.

Antofagasta was 0.3% lower despite the Chilean copper miner reporting positive annual results.

For 2020, revenue was up 3.3% to USD5.13 billion from USD4.94 billion in 2019. Pretax profit was USD1.41 billion, up 4.4% from USD1.35 billion.

The company's preferred metric - earnings before interest, tax, depreciation and amortisation - rose 12% to USD2.74 billion in 2020 from USD2.44 billion the year prior.

The miner declared a final dividend of 48.5 cents per share, bringing the total dividend for the year to 54.7 cents per share, up from 17.8 cents in 2019.

The Japanese Nikkei 225 index ended up 0.5% on Tuesday. In China, the Shanghai Composite closed up 0.8%, while the Hang Seng index in Hong Kong closed up 0.6%. The S&P/ASX 200 in Sydney finished 0.8% higher.

The pound was quoted at USD1.3838 early Tuesday, down from USD1.3885 at the London equities close Monday.

The euro was priced at USD1.1925, lower from USD1.1931. Against the Japanese yen, the dollar was trading at JPY109.15, up from JPY10.08.

Brent oil was priced at USD68.32 a barrel Tuesday morning, lower from USD68.70 late Monday. Gold was trading at USD1,731.45 an ounce, up from USD1,730.28.

The economic events calendar on Tuesday has the ZEW economic sentiment survey for both the eurozone and Germany at 1000 GMT and US retail sales at 1230 GMT.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.